Cytosorbents CorporationCTSONASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank53
3Y CAGR-30.2%
5Y CAGR-10.2%
Year-over-Year Change
Research and development spending
3Y CAGR
-30.2%/yr
vs +18.3%/yr prior
5Y CAGR
-10.2%/yr
Recent deceleration
Acceleration
-48.5pp
Decelerating
Percentile
P53
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $5.14M | -25.7% |
| 2024 | $6.92M | -55.6% |
| 2023 | $15.59M | +3.1% |
| 2022 | $15.12M | -7.7% |
| 2021 | $16.38M | +85.9% |
| 2020 | $8.81M | -27.1% |
| 2019 | $12.09M | +56.6% |
| 2018 | $7.72M | +90.7% |
| 2017 | $4.05M | -15.3% |
| 2016 | $4.78M | - |